{"id":133830,"date":"2022-01-10T02:22:26","date_gmt":"2022-01-10T10:22:26","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/01\/genflow-to-become-europes-first-longevity-biotech-ipo"},"modified":"2022-01-10T02:22:26","modified_gmt":"2022-01-10T10:22:26","slug":"genflow-to-become-europes-first-longevity-biotech-ipo","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/01\/genflow-to-become-europes-first-longevity-biotech-ipo","title":{"rendered":"Genflow to become Europe\u2019s first longevity biotech IPO"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/genflow-to-become-europes-first-longevity-biotech-ipo.jpg\"><\/a><\/p>\n<p>The company is developing novel therapeutics targeting aging in humans and dogs by using genetically modified adeno-associated virus (AAV) vectors to deliver copies of the SIRT6 gene variant found in centenarians. SIRT6 has already been shown to have significant capabilities to repair DNA damage, and Genflow\u2019s aim is to show that it can also improve healthspan and, potentially, increase lifespan. \u201cOur business model is to develop our lead compound, GF-1002, that has already yielded encouraging pre-clinical results,\u201d Leire told us. \u201cWe are currently undertaking pre-clinical trials which are expected to take approximately two years.<\/p>\n<hr>\n<p>SIRT6 targeting longevity biotech announces intention to float on the London Stock Exchange, with IPO later this month.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The company is developing novel therapeutics targeting aging in humans and dogs by using genetically modified adeno-associated virus (AAV) vectors to deliver copies of the SIRT6 gene variant found in centenarians. SIRT6 has already been shown to have significant capabilities to repair DNA damage, and Genflow\u2019s aim is to show that it can also improve [\u2026]<\/p>\n","protected":false},"author":388,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,43,412,269],"tags":[],"class_list":["post-133830","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-business","category-genetics","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/133830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/388"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=133830"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/133830\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=133830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=133830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=133830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}